You are here: Industry Insights > Denali Therapeutics

News List

SIRION Biotech and Denali Therapeutics Join Forces to Develop Gene Therapies for Diseases of the Central Nervous System pharmafocusasia
January 11, 2019
SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene & cell therapy, announced today that it signed a license and collaboration agreement with Denali Therapeutics....
Sanofi teams up with Denali in $1.125bn neurological and inflammatory development deal pharmafile
November 19, 2018
Sanofi has sealed the deal with Denali Therapeutics to leverage the latter’s small molecule candidates in the development of new therapies to tackle a variety of neurological
Sanofi signs $1bn drug development deal with Denali Therapeutics pharmaceutical-technology
November 06, 2018
Sanofi has entered a deal valued at more than $1bn with US-based Denali Therapeutics to advance potential drug candidates for the treatment of neurological and systemic inflammatory diseases.
Denali Therapeutics Adds $155 Million from Takeda biospace
March 20, 2018
Denali Therapeutics Inc., located in South San Francisco, California, had a lot of news to share today.
Denali pulls off 2017’s biggest biotech IPO, pocketing $250M for Parkinson’s, Alzheimer’s trials iercebiotech
December 11, 2017
Denali Therapeutics has raised $250 million. The IPO, the biggest biotech listing of the year, sets Denali up to push drugs against Alzheimer’s and Parkinson’s diseases through early clinical trials.